# Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

> **NCT02941354** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 35 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A

## Interventions

- **DRUG:** turoctocog alfa

## Key facts

- **NCT ID:** NCT02941354
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-10
- **Primary completion:** 2017-06-20
- **Final completion:** 2017-06-20
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02941354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02941354, "Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02941354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*